Allergan, Inc Reports Q4 $1.35 v $1.34e, R$1.68B v $1.65Be
- Guides Q1 $1.09-1.12 v $1.22e; Rev $1.525-1.600B v $1.59Be
- Guides initial FY14 $5.36-5.48 v $5.52e; total net product sales $6.65-6.95B v $6.72Be
- CEO: "We are pleased to have once again achieved our double digit revenue and mid teens earnings per share growth aspirations for full year 2013 as we benefited from many regulatory approvals in the past few years. Furthermore, we look forward to delivering similar revenue and earnings growth in 2014."
- Guides initial FY14 $5.36-5.48 v $5.52e; total net product sales $6.65-6.95B v $6.72Be
- CEO: "We are pleased to have once again achieved our double digit revenue and mid teens earnings per share growth aspirations for full year 2013 as we benefited from many regulatory approvals in the past few years. Furthermore, we look forward to delivering similar revenue and earnings growth in 2014."